Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Good afternoon ladies and gentlemen and thank you for standing by.

VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...

Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC ...

VolitionRx (VNRX) announces the results of a study which shows that an automated Nu.Q Cancer immunoassay test in development detected a range ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow ...

Saber CEO Matthew Karch, whose company used to be part of Embracer alongside Volition, explains what happened to the defunct ...

Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time ...

Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...